Use of the GTPase Rab27B to diagnose and treat poor prognosis estrogen-receptor-positive breast cancer
US9103833B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 12, 2010 |
| Grant date | Aug 11, 2015 |
| Priority date | — |
| Expiry date | Apr 26, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4719
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to evaluating the prognosis of patients with estrogen receptor-positive breast cancer on the basis of Rab27B expression. The invention further relates to a kit comprising an assay for measuring Rab27B levels in said patients and to the usage of Rab27B as a target to screen for drugs capable of inhibiting or diminishing metastasis of said cancer. Furthermore, the invention discloses compounds which can be used to treat estrogen receptor-positive breast cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.